Patents by Inventor Ole Baadsgaard

Ole Baadsgaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF
    Publication number: 20230416403
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: December 6, 2022
    Publication date: December 28, 2023
    Inventors: Sandra VERPLOEGEN, David P. E. SATIJN, Rene M. A. HOET, Paul PARREN, Jan VAN DE WINKEL, Vibeke Miller BREINHOLT, Eva EHRNROOTH, Ole BAADSGAARD, Tom VINK, Willem Karel BLEEKER, Mischa HOUTKAMP, Maroeska OUDSHOORN, Rob N. DE JONG
  • CD38 antibodies for the treatment of human diseases
    Publication number: 20230312742
    Abstract: The present invention relates to antibodies and antigen binding fragment thereof, capable of binding to CD38 antigen. More specifically, the invention relates to antibodies and antigen binding fragments, wherein said antibodies or antigen binding fragments comprises sequences of human origin, and wherein said sequences of human origin reduces immunogenicity compared to a murine antibody. The invention further relates to bispecific antibodies for binding to CD38 and CD3. Further, the invention relates to bispecific antibodies for binding to CD38 and a chelator. The invention further relates to antibodies and antigen binding fragments for the treatment of cancer and autoimmune diseases.
    Type: Application
    Filed: June 14, 2021
    Publication date: October 5, 2023
    Inventors: Ahmed MAHIUDDIN, Linlin WANG, Sayed Shahabuddin HOSEINI, Ole BAADSGAARD, Claus J. MØLLER SAN-PEDRO
  • HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)
    Publication number: 20230042255
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: April 22, 2022
    Publication date: February 9, 2023
    Inventors: Jessica TEELING, Paul PARREN, Ole BAADSGAARD, Debra HUDSON, Jørgen PETERSEN
  • MONOCLONAL ANTIBODIES AGAINST HER2
    Publication number: 20220169738
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: July 7, 2021
    Publication date: June 2, 2022
    Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
  • Methods of treating cancer with human monoclonal antibodies against interleukin 8 (IL-8)
    Patent number: 11339215
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: May 24, 2022
    Assignee: CORMORANT PHARMACEUTICALS AB
    Inventors: Jessica Teeling, Paul Parren, Ole Baadsgaard, Debra Hudson, Jørgen Petersen
  • Monoclonal antibodies against HER2
    Patent number: 11091553
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: August 17, 2021
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
  • Monoclonal antibodies against HER2
    Patent number: 11046771
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: June 29, 2021
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
  • HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF
    Publication number: 20210171657
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: May 21, 2020
    Publication date: June 10, 2021
    Applicants: GENMAB A/S, GENMAB A/S
    Inventors: Sandra VERPLOEGEN, David P.E. SATIJN, Rene M.A. HOET, Paul PARREN, Jan VAN DE WINKEL, Vibeke Miller BREINHOLT, Eva EHRNROOTH, Ole BAADSGAARD, D.M.Sc., Tom VINK, Willem Karel BLEEKER, Mischa HOUTKAMP, Maroeska OUDSHOORN, Rob N. DE JONG
  • MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE
    Publication number: 20210122830
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: August 26, 2020
    Publication date: April 29, 2021
    Inventors: Bart DE GOEIJ, Edward N. VAN DEN BRINK, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, D.M.Sc., David SATIJN, Jan VAN DE WINKEL, Paul PARREN
  • HUMAN MONOCLONAL ANTIBODIES AGAINST CD25
    Publication number: 20210107985
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: May 26, 2020
    Publication date: April 15, 2021
    Inventors: Janine SCHUURMAN, Catharina Emanuele Gerarda HAVENITH, Paul PARREN, Jan G. J. VAN DE WINKEL, Denise Leah WILLIAMS, Jørgen PETERSEN, Ole BAADSGAARD
  • Human Monoclonal Antibodies Against CD20
    Publication number: 20200317799
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: November 20, 2019
    Publication date: October 8, 2020
    Applicant: Genmab A/S
    Inventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G.J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
  • Monoclonal antibodies against HER2 epitope
    Patent number: 10793640
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: October 6, 2020
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Edward N. Van Den Brink, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, David Satijn, Jan Van De Winkel, Paul Parren
  • Human monoclonal antibodies against CD25
    Patent number: 10703818
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: July 7, 2020
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
  • USE OF ANTI-B7H3 ANTIBODIES FOR TREATING CANCER IN THE CENTRAL NERVOUS SYSTEM
    Publication number: 20200197546
    Abstract: The presently disclosed subject matter provides uses of anti-B7H3 antibodies for treating cancers in the central nervous system (CNS), including tumors metastatic to CNS, and in particular leptomeningeal carcinomatosis.
    Type: Application
    Filed: May 14, 2018
    Publication date: June 25, 2020
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, Y-MABS THERAPEUTICS, INC.
    Inventors: Kim Kramer, Cheung Nai-Kong, Ole Baadsgaard, Claus J. Møller San-Pedro
  • COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
    Publication number: 20200114000
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
    Type: Application
    Filed: September 12, 2019
    Publication date: April 16, 2020
    Inventors: Jan VAN DE WINKEL, Paul PARREN, Yvo GRAUS, Judith OPRINS, Michel DE WEERS, Martine VAN VUGT, Ole BAADSGAARD, Steen LISBY
  • HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)
    Publication number: 20190248883
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: February 20, 2019
    Publication date: August 15, 2019
    Inventors: Jessica TEELING, Paul PARREN, Ole BAADSGAARD, D.M.Sc., Debra HUDSON, Jørgen PETERSEN
  • Human Antibodies Against Tissue Factor and Methods of Use Thereof
    Publication number: 20190169311
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: August 16, 2018
    Publication date: June 6, 2019
    Inventors: Sandra Verploegen, David P.E. Satijn, Rene M.A. Hoet, Paul Parren, Jan Van De Winkel, Vibeke Miller Breinholt, Eva Ehrnrooth, Ole Baadsgaard, Tom Vink, Willem Karel Bleeker, Mischa Houtkamp, Maroeska Oudshoorn, Rob N. De Jong
  • Human monoclonal antibodies against interleukin 8 (IL-8)
    Patent number: 10253093
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: April 9, 2019
    Assignee: CORMORANT PHARMACEUTICALS AB
    Inventors: Jessica Teeling, Paul Parren, Ole Baadsgaard, Debra Hudson, Jørgen Petersen
  • HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)
    Publication number: 20180251540
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: April 30, 2018
    Publication date: September 6, 2018
    Inventors: Jessica TEELING, Paul PARREN, Ole BAADSGAARD, Debra HUDSON, Jørgen PETERSEN
  • Human monoclonal antibodies against interleukin 8 (IL-8)
    Patent number: 10066012
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: September 4, 2018
    Assignee: CORMORANT PHARMACEUTICALS AB
    Inventors: Jessica Teeling, Paul Parren, Ole Baadsgaard, Debra Hudson, Jørgen Petersen